What is Albireo Pharma, Inc?
Albireo Pharma, Inc. is a biopharmaceutical company dedicated to developing innovative bile acid modulators for rare pediatric and adult liver diseases. Headquartered in Boston, Massachusetts, with a key operational subsidiary in Gothenburg, Sweden, the company is strategically positioned to address unmet medical needs in this specialized therapeutic area. Its focus on rare diseases indicates a commitment to high-impact, niche markets within the pharmaceutical industry.
How much funding has Albireo Pharma, Inc raised?
Albireo Pharma, Inc has raised a total of $115M across 1 funding round:
Private Equity
$115M
Private Equity (2022): $115M with participation from Sagard
Key Investors in Albireo Pharma, Inc
Sagard
Sagard Holdings is a multi-strategy alternative asset manager that provides flexible capital solutions and partners with entrepreneurs. Their investment in Albireo Pharma suggests a strategic interest in the biopharmaceutical sector, potentially focusing on companies with strong development pipelines.
What's next for Albireo Pharma, Inc?
With the recent influx of capital, Albireo Pharma is poised for significant growth and advancement. The enterprise-level backing suggests a mature stage in the company's lifecycle, likely enabling the progression of late-stage clinical trials and potential commercialization efforts. This strategic investment will likely be channeled into expanding its rare disease portfolio, further solidifying its position as a leader in this critical area of medical research and development.
See full Albireo Pharma, Inc company page
